KPF
JAZZ icon

K2 Principal Fund’s Jazz Pharmaceuticals JAZZ Stock Holding History

K2 Principal Fund’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,561
Closed -$501K – 245
2015
Q4 		$501K Sell
3,561
-10,200
-74% -$1.41M 0.07% 147
2015
Q3 		$1.83M Buy
13,761
+12,163
+761% +$2.09M 0.3% 73
2015
Q2 		$281K Sell
1,598
-1,202
-43% -$216K 0.05% 143
2015
Q1 		$484K Buy
2,800
+400
+17% +$68.7K 0.1% 117
2014
Q4 		$393K Buy
+2,400
New +$398K 0.09% 123

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

K2 Principal Fund's JAZZ Position: Q1 2016 in Review

K2 Principal Fund sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2016, closing a stake of 3,561 shares — an estimated $501K sold.

K2 Principal Fund first reported a position in JAZZ in Q4 2014 and held it in 5 quarters. The position peaked at $1.83M in Q3 2015. 339 funds tracked by Wall St. Rank hold JAZZ as of Q1 2016.

  • K2 Principal Fund reported no remaining Jazz Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • K2 Principal Fund sold 3,561 Jazz Pharmaceuticals shares in Q1 2016, an estimated $501K.
  • K2 Principal Fund first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • K2 Principal Fund's Jazz Pharmaceuticals position peaked at $1.83M in Q3 2015.
  • 339 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2016.

Based on K2 Principal Fund's 13F filing for Q1 2016, filed 12 May 2016.